ProBiotix Health highlights LPLDL® and new products to support cardiometabolic health at SupplySide West
ProBiotix Health plc (‘ProBiotix’) will be highlighting the advantages of LPLDL®, its patented science-backed probiotic strain for cardiometabolic health in a range of new formats at this year’s biggest tradeshow for food and dietary supplement manufacturers, SupplySide West, held in Mandalay Bay, Las Vegas.
On 25 and 26 October, ProBiotix will use the event to showcase CholBiome® Daily Maintenance in capsule and fast melt stick pack applications.
CholBiome® harnesses the power of LPLDL® to offer a safe, effective, and natural solution for cardiometabolic health.
The efficacy of the product resulted in ProBiotix recently achieving Structure Function Claims* for consumer packaging and promotional materials in the US. These claims indicate that LPLDL® with CholBiome® ‘helps maintain cholesterol levels already in the normal range’, ‘supports normal LDL and HDL cholesterol levels’, has a ‘positive effect on cholesterol levels within the normal range’ and ‘benefits long term cardiovascular health’.
Steen Andersen, CEO of ProBiotix who will be present at the exhibition booth 7449, said: “LPLDL® with CholBiome® acts on internal cholesterol-producing enzymes that break down bile salts, which then forces the liver to remove the cholesterol from the blood to replenish the body’s bile salt levels.
“LPLDL® is also available in a range of other finished formulation formats developed by ProBiotix Health. The finished formulation range, CholBiome® utilizes specialized active ingredients for a multi-targeted approach to target key areas of cardiometabolic health, including cholesterol, hypertension, and vascular health, and is designed to be convenient, effective, and a scientifically validated solution.”
In addition to CholBiome®, ProBiotix will also showcase new product development for LPLDL®, including its new fast melts stick pack. This is an easy and fun way to take CholBiome® as it melts instantly on the tongue and imparts a deliciously fresh fruit flavor. Samples will be available at the booth in redberry and peach flavors.
Cellan Davies, Marketing Manager of ProBiotix who will also be present, said:
“ProBiotix’s formulations that include LPLDL® are backed by multiple independent human intervention studies conducted at several leading UK Universities. These clearly show its efficacy and impact on cardiometabolic health.
“In our double-blind, randomized, and placebo-controlled study at the University of Reading, participants taking LPLDL® daily found that multiple cardiometabolic biomarkers were improved, including a reduction in total cholesterol by up to 36%, lowering of LDL cholesterol by almost 14% and an increase in HDL cholesterol by up to 4.5%,” Cellan noted.
“Furthermore, a 9-week study by the University of Roehampton aimed to investigate the cholesterol-lowering efficacy of LPLDL® in hypercholesterolaemic adults found statistically significant reductions in multiple cardiometabolic biomarkers, including lowering total cholesterol by 34%, LDL cholesterol by 28%, non-HDL cholesterol by 17%, and ApoB by 28%.”
As part of its new strategic vision, ProBiotix Health will also be showcasing CholBiome®CH, which was recently nominated for a CPHI Pharma Award in the finished formulation category. The CholBiome® range that includes LPLDL® is furthermore augmented by CholBiome®BP, CholBiome®X3, and CholBiome®VH as finished dosage format supplements for health brands and retailers to rebrand as a private-label food supplement.
ProBiotix will exhibit at Booth 7449. To arrange a meeting with Steen or Director Business Development for North America, Zac Sniderman, please arrange a session via the SupplySide West website, or directly via LinkedIn.
For more information on the CholBiome® range of products, please visit lpldl.com
* These statements have not been evaluated by the Food and Drug Administration. The product is not intended to diagnose, treat, cure, or prevent any disease.